AI Article Synopsis
- The text discusses the significant medical concern of reactivating hepatitis B in patients undergoing immunosuppressive therapy for skin conditions, highlighting its relevance across various medical fields.
- It presents an evidence-based algorithm for managing patients who have apparently cleared hepatitis B, focusing on the risks associated with specific immunosuppressive drugs.
- Recommendations for antiviral prophylaxis, laboratory monitoring, and the potential benefits of booster vaccination to reduce reactivation risk are also included.
Article Abstract
The association between immunosuppressive therapy for dermatologic conditions and the subsequent reactivation of hepatitis B is of major medical concern. It remains a point of interest across multiple disciplines, including hepatology, dermatology, rheumatology, and infectious disease. Accordingly, we present an evidence-based practice algorithm on how best to approach a patient with presumptively cleared hepatitis B infection when anticipating the initiation of immunosuppressive therapy. This guide delineates the risk of reactivation by taking into account the immunosuppressive agent of choice and presents recommendations for antiviral prophylaxis and laboratory monitoring. Booster vaccination as a potential to decrease the risk of hepatitis B reactivation is likewise discussed. (. 2021;19:-0).
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!